A proposed securities class action has been filed on behalf of investors who acquired Hims & Hers Health, Inc. securities between Aug. 4, 2025, and July 29, 2026. The complaint alleges that Hims shared consumers' protected health information with third-party advertising platforms, charged for prescriptions shortly after intake forms were submitted, and made misleading statements about its operations and prospects while facing potential regulatory scrutiny, fees and penalties. The Federal Trade Commission sued Hims on July 29, 2026, alleging that the telehealth provider improperly shared sensitive medical information with advertising platforms and used deceptive billing and cancellation practices. Hims shares fell $4.32, or 14.73%, to close at $25.00 that day. Investors seeking appointment as lead plaintiff have until Nov. 2, 2026, although participation in any potential recovery does not require serving in that role.